首页> 外文期刊>Radiology and Oncology >Results of photon radiotherapy for unresectable salivary gland tumors: is neutron radiotherapy’s local control superior?
【24h】

Results of photon radiotherapy for unresectable salivary gland tumors: is neutron radiotherapy’s local control superior?

机译:光子放射疗法治疗无法切除的涎腺肿瘤的结果:中子放射疗法的局部控制效果更好吗?

获取原文
           

摘要

Background. The results of RTOG-MRC randomized trial of photon (n=15) versus neutron (n=17) therapy in the 1980a€?s reported an improved local control (LC) with neutron radiotherapy for unresectable salivary gland tumors. Due to increased severe toxicity with neutron radiotherapy and the paucity of neutron-therapy centers, we analyzed our institutiona€?s results of photon radiotherapy for unresectable salivary gland tumors. Patients and methods. From 1990 to 2009, 27 patients with unresectable salivary gland cancer underwent definitive photon radiotherapy at our institution. Nodal involvement on presentation was found in 9 patients. Median dose of radiotherapy was 70 Gy. Chemotherapy was given to 18 patients, most being platinum-based regimens. Local control (LC), locoregional control (LRC), distant metastasis-free survival (DMFS), overall survival (OS), and toxicity outcomes were assessed. Results. With a median follow-up of 52.4 months, the 2/5-year actuarial LC was 69% (95%CI ?± 21.0%)/55% (?± 24.2%), LRC was 65% (?± 21.4%)/47% (?± 21.6%), and DMFS was 71% (?± 21.8%)/51% (?± 22.8%), respectively using competing risk analysis. The median OS was 25.7 months, and the 2/5-year OS rates were 50% (?± 19.0%)/29% (?± 16.6%), respectively. Higher histologic grade was significant for an increased rate of DM (intermediate grade vs. low grade, p=0.04, HR 7.93; high grade vs. low grade, p=0.01, HR 13.50). Thirteen (48%) patienta€?s experienced acute grade 3 toxicity. Late grade 3 toxicity occurred in three (11%) patients. Conclusions. Our data compares favorably to neutron radiotherapy with fewer late complications. Photon radiotherapy is an acceptable alternative to neutron radiotherapy in patients who present with unresectable salivary gland tumors.
机译:背景。 RTOG-MRC在1980年代对光子(n = 15)与中子(n = 17)疗法进行随机试验的结果报道,中子放疗对不可切除的涎腺肿瘤的局部控制(LC)有所改善。由于中子放疗的严重毒性增加以及中子治疗中心的匮乏,我们分析了我们机构对无法切除的唾液腺肿瘤进行光子放疗的结果。患者和方法。从1990年到2009年,我们机构对27例无法切除的涎腺癌患者进行了明确的光子放疗。 9例患者发现淋巴结受累。放射治疗的中位剂量为70 Gy。对18例患者进行了化学疗法,大多数为铂类疗法。评估了局部控制(LC),局部区域控制(LRC),无远处转移生存期(DMFS),总生存期(OS)和毒性结果。结果。平均随访52.4个月,2/5年的精算LC为69%(95%CI±21.0%)/ 55%(±24.2%),LRC为65%(±21.4%)使用竞争风险分析,分别为/ 47%(?±21.6%)和DMFS为71%(?±21.8%)/ 51%(?±22.8%)。中位OS为25.7个月,而2/5年OS率为50%(±19.0%)/ 29%(±16.6%)。较高的组织学等级对于DM的发生率具有显着意义(中级与低级,p = 0.04,HR 7.93;高级与低级,p = 0.01,HR 13.50)。十三名(48%)患者经历了急性3级毒性。三名(11%)患者发生了晚期3级毒性。结论。我们的数据优于中子放疗,后期并发症更少。对于存在无法切除的唾液腺肿瘤的患者,光子放疗是中子放疗的一种可接受的替代方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号